Risk of recurrent venous thrombosis for strata of free protein S levels
| Range . | Observation years (relatives) . | Relatives with event . | Annual incidence, % (95% CI) . | Crude HR (95% CI) . | Adjusted HR* (95% CI) . | Adjusted HR† (95% CI) . | Adjusted HR (95% CI) adjusted for . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Antithrombin deficiency . | Protein C deficiency . | Factor V Leiden . | Prothrombin G20210A . | High factor VIII . | |||||||
| > 75th percentile (> 91 IU/dL) | 121 (n = 12) | 5 | 4.13 (1.34–9.64) | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference |
| 50th–75th percentile(79–90 IU/dL) | 145(n = 14) | 3 | 2.07(0.43–6.05) | 0.5(0.1–2.3) | 0.6(0.2–2.3) | 0.7(0.2–3.4) | 1.2(0.2–6.5) | 0.6(0.1–2.3) | 0.5(0.1–2.1) | 0.4(0.1–2.3) | 0.6(0.1–2.4) |
| 25th–50th percentile(65–78 IU/dL) | 241(n = 25) | 4 | 1.66(0.45–4.25) | 0.5(0.1–1.7) | 0.5(0.2–1.9) | 0.9(0.2–3.4) | 0.9(0.2–4.0) | 0.4(0.1–1.6) | 0.4(0.1–1.5) | 0.4(0.1–1.3) | 0.7(0.1–3.5) |
| 5th–25th percentile(41–64 IU/dL) | 228(n = 14) | 5 | 2.19(0.71–5.12) | 0.6(0.2–2.3) | 0.7(0.2–2.6) | 0.7(0.2–2.7) | 0.6(0.6–2.1) | 0.7(0.2–2.4) | 0.5(0.1–1.9) | 0.8(0.2–2.7) | 0.7(0.2–2.4) |
| < 5th percentile(< 41 IU/dL) | 66(n = 11) | 8 | 12.12(5.23–23.88) | 2.8(0.9–8.6) | 3.0(1.03–8.5) | 3.1(0.9–10.8) | 4.3(1.2–15.0) | 2.7(0.9–8.3) | 2.5(0.8–8.0) | 2.2(0.7–7.4) | 4.4(1.2–15.9) |
| < 2.5th percentile(< 33 IU/dL) | 55(n = 10) | 7 | 12.73(5.12–26.22) | 3.1(0.95–10.0) | 3.4(1.1–10.3) | 3.1(0.9–10.8) | 4.6(1.3–16.7) | 4.7(1.2–17.6) | 2.9(0.8–10.3) | 2.5(0.7–9.1) | 4.6(1.2–16.9) |
| Range . | Observation years (relatives) . | Relatives with event . | Annual incidence, % (95% CI) . | Crude HR (95% CI) . | Adjusted HR* (95% CI) . | Adjusted HR† (95% CI) . | Adjusted HR (95% CI) adjusted for . | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Antithrombin deficiency . | Protein C deficiency . | Factor V Leiden . | Prothrombin G20210A . | High factor VIII . | |||||||
| > 75th percentile (> 91 IU/dL) | 121 (n = 12) | 5 | 4.13 (1.34–9.64) | Reference | Reference | Reference | Reference | Reference | Reference | Reference | Reference |
| 50th–75th percentile(79–90 IU/dL) | 145(n = 14) | 3 | 2.07(0.43–6.05) | 0.5(0.1–2.3) | 0.6(0.2–2.3) | 0.7(0.2–3.4) | 1.2(0.2–6.5) | 0.6(0.1–2.3) | 0.5(0.1–2.1) | 0.4(0.1–2.3) | 0.6(0.1–2.4) |
| 25th–50th percentile(65–78 IU/dL) | 241(n = 25) | 4 | 1.66(0.45–4.25) | 0.5(0.1–1.7) | 0.5(0.2–1.9) | 0.9(0.2–3.4) | 0.9(0.2–4.0) | 0.4(0.1–1.6) | 0.4(0.1–1.5) | 0.4(0.1–1.3) | 0.7(0.1–3.5) |
| 5th–25th percentile(41–64 IU/dL) | 228(n = 14) | 5 | 2.19(0.71–5.12) | 0.6(0.2–2.3) | 0.7(0.2–2.6) | 0.7(0.2–2.7) | 0.6(0.6–2.1) | 0.7(0.2–2.4) | 0.5(0.1–1.9) | 0.8(0.2–2.7) | 0.7(0.2–2.4) |
| < 5th percentile(< 41 IU/dL) | 66(n = 11) | 8 | 12.12(5.23–23.88) | 2.8(0.9–8.6) | 3.0(1.03–8.5) | 3.1(0.9–10.8) | 4.3(1.2–15.0) | 2.7(0.9–8.3) | 2.5(0.8–8.0) | 2.2(0.7–7.4) | 4.4(1.2–15.9) |
| < 2.5th percentile(< 33 IU/dL) | 55(n = 10) | 7 | 12.73(5.12–26.22) | 3.1(0.95–10.0) | 3.4(1.1–10.3) | 3.1(0.9–10.8) | 4.6(1.3–16.7) | 4.7(1.2–17.6) | 2.9(0.8–10.3) | 2.5(0.7–9.1) | 4.6(1.2–16.9) |